{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:24:06Z","timestamp":1794857046926,"version":"4.9.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1395,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["British Journal of Urology"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:p>Objective\u2002To study the effect of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate (PM) on patients in whom previous intracavernosal therapy had failed.<\/jats:p>\n                  <jats:p>Patients and method\u2002The study comprised 70 consecutive patients attending a clinic for erectile dysfunction, in whom previous therapy with intracavernosal prostaglandin\u2010E1 (20\u2003\u03bcg and papaverine (30\u2003mg) combined with 1\u2003mg PM had failed. They were given intracavernosal injections, initially with 25\u2003\u03bcg VIP\/1\u2003mg PM (VIP1) and if unsuccessful, 25\u2003\u03bcg VIP\/2\u2003mg PM (VIP2). Both VIP1 and VIP2 were administered using a pre\u2010filled ready\u2010to\u2010use autoinjector fitted with a 29\u2003G needle. The patients were diagnosed as having spinal cord lesion (eight), diabetes (21), ischaemic heart disease (12), hypertension (six), other diagnoses (nine), or idiopathic causes (14).<\/jats:p>\n                  <jats:p>Result\u2002Forty\u2010seven (67%) of patients achieved erections sufficient for sexual intercourse (33 on VIP1 and 14 on VIP2), initially under clinical supervision and subsequently during home use. Minor side\u2010effects were transient facial flushing in 37 (53%), truncal flushing in six (9%), bruising in 14 (20%) and pain from the injection needle in eight (11%). No patients reported priapism or other serious adverse events.<\/jats:p>\n                  <jats:p>Conclusion\u2002The combination of VIP and PM at the dose used was a safe and effective treatment in patients in whom other therapies had failed.<\/jats:p>","DOI":"10.1046\/j.1464-410x.1998.00564.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:36:56Z","timestamp":1047350216000},"page":"437-440","source":"Crossref","is-referenced-by-count":31,"title":["Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents"],"prefix":"10.1111","volume":"81","author":[{"family":"Dinsmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alderdice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Impotence. National Institutes of Health Consensus Statement.10; 1 December 1992"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)34871-1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0094-0143(21)01262-3","article-title":"Causes and classification of impotence.","volume":"8","author":"Smith AD","year":"1981","journal-title":"Urol Clin North Am"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00251005"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90910-2"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331978403500203"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.4.332"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39864-6"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1992.tb15568.x"},{"key":"e_1_2_6_11_1","first-page":"71","article-title":"Pharmacotherapy of erectile dysfunction. A review.","volume":"1","author":"Juenemann KP","year":"1989","journal-title":"Int J Impot Res"},{"key":"e_1_2_6_12_1","first-page":"151","article-title":"Final results of a prospective multicentre study with self\u2010injection therapy with PGE1, after 4 years of follow\u2010up.","volume":"8","author":"Porst H","year":"1996","journal-title":"Int J Impot Res"},{"key":"e_1_2_6_13_1","first-page":"143","article-title":"Penile fibrosis during 18 months of intracavernosal therapy with alprostadil (Caverject).","volume":"8","author":"Linet OI","year":"1996","journal-title":"Int J Impot Res"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)40208-4"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604043341401"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90471-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92687-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43406-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44763-X"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37541-9"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(86)90170-1"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6410.9"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39939-1"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42059-3"}],"container-title":["British Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.1998.00564.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410x.1998.00564.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:53:45Z","timestamp":1761742425000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410x.1998.00564.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1046\/j.1464-410x.1998.00564.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.1998.00564.x","archive":["Portico"],"relation":{},"ISSN":["0007-1331"],"issn-type":[{"value":"0007-1331","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}